Abstracts tagged "RANK/RANKL pathway"

Abstract Number: 1281 • 2012 ACR/ARHP Annual Meeting
IL-6 Signaling Inhibition Improves Abnormal Bone Homeostasis in Active Rheumatoid Arthritis
Masayasu Kitano¹, Sachie Kitano¹, Chieri Sato¹, Kazuyuki Fujita¹, Takahiro Yoshikawa¹, Yuki Katashima¹, Masahiro Sekiguchi¹, Naoto Azuma¹, Naoaki Hashimoto, Shinichiro Tsunoda¹, Kiyoshi Matsui¹ and Hajime Sano¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan
Background/Purpose: Tocilizumab (TCZ) is a humanized monoclonal anti-IL-6 receptor antibody. TCZ has demonstrated efficacy in moderate to severe active rheumatoid arthritis (RA) with inadequate clinical…
Abstract Number: 1207 • 2012 ACR/ARHP Annual Meeting
Impact of Anti Tumor Necrosis Factor-Alpha Therapy in Rheumatoid Arthritis On Osteoclast Activation and B Cells
Ezinma Ezealah¹, Jennifer Hossler¹, Jamie Biear¹, Christopher A. Cistrone¹, Teresa Owen¹, Nida Meednu¹, Kelly Callahan¹, Arumugam Palanichamy¹, Ignacio Sanz², Allen P. Anandarajah¹, Ralf G. Thiele¹, Darren Tabechian³, R. John Looney¹ and Jennifer H. Anolik¹, ¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Rheumatology, Emory University, Atlanta, GA, ³Allergy/Immun/Rheumatology, Univ of Rochester Schl of Med, Rochester, NY
Background/Purpose: Serum receptor activator of NFkB ligand (RANKL) and its natural decoy receptor, osteoprotegerin (OPG), play key roles in osteoclast activation. In a group of…
Abstract Number: 726 • 2012 ACR/ARHP Annual Meeting
Dynamic in Vivo Imaging of Th17-Mediated Osteoclastic Bone Resorption in Live Bones by Using Intravital Multiphoton Microscopy
Junichi Kikuta and Masaru Ishii, Laboratory of Cellular Dynamics, Immunology Frontier Research Center, Osaka University, Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint synovial inflammation and progressive cartilage/bone destruction. Although various kinds of cell types, such…
Abstract Number: 45 • 2012 ACR/ARHP Annual Meeting
The Effects of Apremilast On Osteoclasts, Osteoblasts, and Osteocytes
Mary Adams and Peter Schafer, Department of Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose: Apremilast (APR), a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro- and anti-inflammatory mediator production in both immune and non-immune…
Abstract Number: 2666 • 2012 ACR/ARHP Annual Meeting
A Link Between B Cells and Bone Erosion in RA: RANKL Production by Memory B Cells
Nida Meednu¹, Teresa Owen², Hengwei Zhang³, Christopher A. Cistrone¹, Lianping Xing⁴ and Jennifer H. Anolik⁵, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Allergy, Immununolgy and Rheumatology,, University of Rochester, Rochester, NY, ³Pathology and Laboratory Medicine, University of Rochester, Rochester, NY, ⁴Pathology & Lab Medicine, University of Rochester, Rochester, NY, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disorder that often leads to joint damage. Several lines of evidence suggests the role of B cells…
Abstract Number: 2312 • 2012 ACR/ARHP Annual Meeting
Senescent T Cells Promote Bone Loss in Rheumatoid Arthritis
Johannes Fessler¹, Rusmir Husic², Elisabeth Lerchbaum³, Verena Schwetz³, Claudia Stiegler³, Barbara Obermayer-Pietsch³, Winfried B. Graninger⁴ and Christian Dejaco⁵, ¹Rheumatology and Immunology, Medical University Graz, Graz, Austria, ²Rheumatology, Medical University Graz, Graz, Austria, ³Division of Endocrinology and Metabolism, Medical University Graz, Graz, Austria, ⁴Internal medicine/Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁵Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom
Background/Purpose: To study the influence of aged CD28-T cells on systemic osteoporosis in rheumatoid arthritis (RA) patients. Methods: Prospective, cross-sectional study on 100 patients with…
Abstract Number: 1992 • 2012 ACR/ARHP Annual Meeting
Anti-TNF Therapies Improve Bone Mineral Density At the Lumbar Spine of RA Patients by Decreasing Disease Activity and Suppressing Serum RANKL Levels
Allen P. Anandarajah¹, Jennifer Hossler², Kate Burns³, Kelly Callahan³, Yahui Grace Chiu³ and Jennifer H. Anolik⁴, ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²Rheumatology, University of Rochester, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Generalized bone loss (osteoporosis or osteopenia) is more common in patients with rheumatoid arthritis (RA) than in the general population. Recent studies suggest that…
Abstract Number: 1997 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Denosumab Vs Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates: A Randomized, Open-Label Study
Michael A. Bolognese¹, Edward Czerwinski², Henry G. Bone³, Sydney Bonnick⁴, Neil Binkley⁵, Alfred Moffett Jr.⁶, Suresh Siddhanti⁷, Irene Ferreira⁸, Prayashi Ghelani⁹, Rachel Wagman⁷, Jesse W. Hall⁷ and Chris Recknor¹⁰, ¹Bethesda Health Research Center, Bethesda, MD, ²Krakow Medical Center, Krakow, Poland, ³Michigan Bone and Mineral Clinic, Detroit, MI, ⁴Clinical Research Center of North Texas, Denton, TX, ⁵University of Wisconsin, Madison, WI, ⁶OB-GYN Associates of Mid Florida, PA, Leesburg, FL, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Amgen Inc., Cambridge, United Kingdom, ⁹Ovatech Solutions, London, United Kingdom, ¹⁰United Osteoporosis Centers, Gainesville, GA
Background/Purpose: Denosumab, a fully human monoclonal antibody that specifically targets RANKL to inhibit osteoclast formation, function, and survival, reduces risk for vertebral, non-vertebral, and hip…
Abstract Number: 1962 • 2012 ACR/ARHP Annual Meeting
The Specific Role of Glutaredoxin2 Isoform b (Glrx2b) in RANKL-Induced Osteoclastogenesis Through Activation of the p38-MAPK Signaling Pathway
Chang-Hoon Lee¹, Wan-Hee Yoo², Jin-Jung Choi³, Myong-Joo Hong⁴, Ji-Min Kim⁵ and Jeong-Tae Yeon⁶, ¹Department of Internal Medicine, School of medicine, Wonkwang university, Iksan, Chonbuk, South Korea, ²Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ³Internal Medicine, CHA University Hospital, Seongnam, South Korea, ⁴Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea, ⁶Department of anatomy, school of medicine, Wonkwang university, Iksan, Chonbuk, South Korea
Background/Purpose: Recently, reactive oxygen species (ROS) and antioxidant enzymes were shown to be closely associated with RANKL-mediated osteoclast differentiation. Although glutaredoxin2 (Glrx2) plays a role…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].